Case Number:

IPR2020-01053

Case Type:

IPR

Status:

Final Written Decision

Petitioner:

Slayback Pharma LLC

Patent Owner:

Sumitomo Dainippon Pharma Co., Ltd.

Tech Center:

1600

1. Filed: June 05, 2020 00:00

   Coverage

   1. January 21, 2022

      Slayback Gets PTAB To Wipe Out Schizophrenia Treatment IP

      The Patent Trial and Appeal Board has invalidated dozens of claims in a Sumitomo Dainippon Pharma patent for treating schizophrenia without certain side effects, finding that the claims were obvious.

   ---

   Stay ahead of the curve

   In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

   
   

   • Search PTAB cases and full-text documents.
   • Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
   • Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!

   TRY LAW360 FREE FOR SEVEN DAYS

   View the PTAB case documents

   Already a subscriber? Click here to login